PT150 Drug for Use in Alcohol Use Disorder
Pop Test Oncology LLC · with University of Kentucky, National Institute on Alcohol Abuse and Alcoholism (NIAAA) · NCT06712602
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 21–55 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 1
- Target enrollment
- 34
- US sites recruiting
- 1
- Study start
- February 1, 2025
- Record last updated
- September 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this study is to learn if PT150 can reduce the behavioral and physical effects of stress, alcohol, and alcohol use in people with alcohol use disorder.
Being studied: alcohol; Stress-Induction; PT150
Conditions: Alcohol Use Disorder
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Meet diagnostic criteria for AUD (moderate or severe) per the Diagnostic and Statistical Manual of Mental Disorders - 5th edition (DSM-5)
Not seeking treatment at the time of the study
English-speaking
Between the ages of 21 and 55 years (individuals under 21 are excluded based on the recommendations of NIAAA that alcohol should not be administered to individuals under the legal drinking age)
Abstinent from alcohol no more than 3 days per week on average
Physically and psychiatrically healthy other than the diagnoses for AUD or tobacco use disorder
ECG, read by cardiologist, within normal limits
Body mass index of 19 - 35
Using an effective form of birth control (e.g., birth control pills, surgical sterilization, condoms, IUD, cervical cap with a spermicide or abstinence) if female
Able to abstain from ALC for 12 hours prior to sessions
No contraindications to ALC or PT150
Exclusion Criteria
Meet diagnostic criteria for SUDs, save nicotine, other than AUD that in the opinion of a study physician would require medical intervention (e.g., opioid use disorder) or compromise the well-being of the participant
Have abnormal blood chemistry, complete blood count or urinalysis values deemed clinically significant
Have a history of serious physical disease or current physical disease (e.g., impaired cardiovascular functioning, histories of seizure, head trauma or CNS tumors)
Have a current or past history of psychiatric disorder that would interfere with participation (e.g., psychotic [schizophrenia, schizoaffective]), bipolar, major depressive disorder)
Have had suicidal ideations in the past 90 days
Pregnant or nursing
Are unwilling/unable to comply with study procedures
Participants scoring >6 on the Clinical Institute Withdrawal Assessment for Alcohol Revised (CIWA-Ar); the CIWA-Ar will be administered prior to each experimental session participants who score >6 will be excluded further participation.
Recruiting US locations
University of Kentucky
Lexington, KY 40506
Site contact: Kelsey Padgett · 859-257-5794 · ktpa223@uky.edu
Study contacts (from the official record)
- Mark Fillmore, PhD · 859-257-4728 · Fillmore@uky.edu
- Kelsey Padgett, PhD · 859-257-5794 · Ktpa223@uky.edu
Similar studies in Kentucky
All phase 1 studies in Kentucky →- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- Louisville, KY + 14 other US sites
- Eligibility basics
- Ages 2 mo–1
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Xencor, Inc.
- Location
- Louisville, KY + 27 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
Gilead Sciences
- Location
- Louisville, KY + 4 other US sites
- Eligibility basics
- Ages 18–69
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Louisville, KY + 18 other US sites
- Eligibility basics
- Ages 18–100